JP2016511257A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016511257A5 JP2016511257A5 JP2015560312A JP2015560312A JP2016511257A5 JP 2016511257 A5 JP2016511257 A5 JP 2016511257A5 JP 2015560312 A JP2015560312 A JP 2015560312A JP 2015560312 A JP2015560312 A JP 2015560312A JP 2016511257 A5 JP2016511257 A5 JP 2016511257A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- item
- composition
- dna damaging
- damaging agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000011510 cancer Diseases 0.000 claims description 77
- 206010028980 Neoplasm Diseases 0.000 claims description 58
- 239000000427 antigen Substances 0.000 claims description 39
- 102000036639 antigens Human genes 0.000 claims description 39
- 108091007433 antigens Proteins 0.000 claims description 39
- 239000012623 DNA damaging agent Substances 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 31
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 19
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 17
- 229960002949 fluorouracil Drugs 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 16
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 12
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 12
- 229960004316 cisplatin Drugs 0.000 claims description 12
- 229960004768 irinotecan Drugs 0.000 claims description 12
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 12
- 230000035945 sensitivity Effects 0.000 claims description 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 9
- 201000002528 pancreatic cancer Diseases 0.000 claims description 9
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 9
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 229940127121 immunoconjugate Drugs 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 5
- 206010027476 Metastases Diseases 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 201000004101 esophageal cancer Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 230000002195 synergetic effect Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 2
- 208000027124 goblet cell carcinoma Diseases 0.000 claims 16
- 230000004614 tumor growth Effects 0.000 claims 2
- 208000012766 Growth delay Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 115
- 230000000340 anti-metabolite Effects 0.000 description 25
- 229940100197 antimetabolite Drugs 0.000 description 25
- 239000002256 antimetabolite Substances 0.000 description 25
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 16
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 16
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 8
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 8
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 8
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 8
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 8
- 229960000485 methotrexate Drugs 0.000 description 8
- 229960003087 tioguanine Drugs 0.000 description 8
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 8
- 229960005277 gemcitabine Drugs 0.000 description 7
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 7
- 229940100198 alkylating agent Drugs 0.000 description 5
- 239000002168 alkylating agent Substances 0.000 description 5
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 4
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 4
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 4
- 102000015790 Asparaginase Human genes 0.000 description 4
- 108010024976 Asparaginase Proteins 0.000 description 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 4
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 4
- 229960003272 asparaginase Drugs 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 4
- 229960002170 azathioprine Drugs 0.000 description 4
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 4
- 229960004117 capecitabine Drugs 0.000 description 4
- 229960002436 cladribine Drugs 0.000 description 4
- 229960000684 cytarabine Drugs 0.000 description 4
- 229940104302 cytosine Drugs 0.000 description 4
- 229960000961 floxuridine Drugs 0.000 description 4
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 4
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 4
- 235000008191 folinic acid Nutrition 0.000 description 4
- 239000011672 folinic acid Substances 0.000 description 4
- 229960001691 leucovorin Drugs 0.000 description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 229960005079 pemetrexed Drugs 0.000 description 4
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 4
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 4
- 229960002340 pentostatin Drugs 0.000 description 4
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 4
- 229960000611 pyrimethamine Drugs 0.000 description 4
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 4
- 229960001082 trimethoprim Drugs 0.000 description 4
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940045799 anthracyclines and related substance Drugs 0.000 description 3
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
- 229940127093 camptothecin Drugs 0.000 description 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 3
- 229960004562 carboplatin Drugs 0.000 description 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 3
- 229960000390 fludarabine Drugs 0.000 description 3
- 229950007221 nedaplatin Drugs 0.000 description 3
- 229960001756 oxaliplatin Drugs 0.000 description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229960005399 satraplatin Drugs 0.000 description 3
- 190014017285 satraplatin Chemical compound 0.000 description 3
- 229960000303 topotecan Drugs 0.000 description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 3
- 239000012625 DNA intercalator Substances 0.000 description 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 2
- -1 anthracycline Substances 0.000 description 2
- 229940125507 complex inhibitor Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361770802P | 2013-02-28 | 2013-02-28 | |
| US61/770,802 | 2013-02-28 | ||
| US201361892854P | 2013-10-18 | 2013-10-18 | |
| US61/892,854 | 2013-10-18 | ||
| PCT/US2014/019034 WO2014134311A1 (en) | 2013-02-28 | 2014-02-27 | Administration of an anti-gcc antibody-drug conjugate and a dna damaging agent in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016511257A JP2016511257A (ja) | 2016-04-14 |
| JP2016511257A5 true JP2016511257A5 (enExample) | 2017-06-15 |
Family
ID=51428806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560312A Pending JP2016511257A (ja) | 2013-02-28 | 2014-02-27 | 癌の治療における抗ｇｃｃ抗体−薬物複合体及びｄｎａ損傷剤の投与 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20140356383A1 (enExample) |
| EP (1) | EP2961424A4 (enExample) |
| JP (1) | JP2016511257A (enExample) |
| KR (1) | KR20150122730A (enExample) |
| CN (1) | CN105142664A (enExample) |
| CA (1) | CA2902757A1 (enExample) |
| TW (1) | TW201444577A (enExample) |
| WO (1) | WO2014134311A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011050242A1 (en) | 2009-10-23 | 2011-04-28 | Millennium Pharmaceuticals, Inc. | Anti-gcc antibody molecules and related compositions and methods |
| EP2841575B1 (en) * | 2012-04-27 | 2019-06-26 | Millennium Pharmaceuticals, Inc. | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy |
| WO2021205325A1 (en) * | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anti-gucy2c antibodies and uses thereof |
| KR20250046283A (ko) | 2022-08-05 | 2025-04-02 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Gucy2c 및 cd3에 특이적으로 결합하는 항원 결합 분자 및 이의 의약적 용도 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6844153B2 (en) * | 2000-03-27 | 2005-01-18 | Thomas Jefferson University | Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| CA2745288A1 (en) * | 2008-12-03 | 2010-06-10 | Alisa Kabcenell | Antibodies for guanylyl cyclase receptors |
| WO2011050242A1 (en) * | 2009-10-23 | 2011-04-28 | Millennium Pharmaceuticals, Inc. | Anti-gcc antibody molecules and related compositions and methods |
-
2014
- 2014-02-27 CA CA2902757A patent/CA2902757A1/en not_active Abandoned
- 2014-02-27 JP JP2015560312A patent/JP2016511257A/ja active Pending
- 2014-02-27 TW TW103106933A patent/TW201444577A/zh unknown
- 2014-02-27 EP EP14756404.1A patent/EP2961424A4/en not_active Withdrawn
- 2014-02-27 CN CN201480023899.7A patent/CN105142664A/zh active Pending
- 2014-02-27 KR KR1020157026431A patent/KR20150122730A/ko not_active Withdrawn
- 2014-02-27 WO PCT/US2014/019034 patent/WO2014134311A1/en not_active Ceased
- 2014-02-27 US US14/192,632 patent/US20140356383A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018518454A5 (enExample) | ||
| ES2749098T3 (es) | Anticuerpos ANTI-B7-H1 y ANTI-CTLA-4 para tratar el cáncer de pulmón no microcítico | |
| JP2015532292A5 (enExample) | ||
| JP2019519499A5 (enExample) | ||
| HRP20220399T1 (hr) | Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost | |
| US20220144943A1 (en) | Anti-cd47 antibodies and uses thereof | |
| JP2018508512A5 (enExample) | ||
| JP2017533912A5 (enExample) | ||
| JP2016536361A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| FI3791896T3 (fi) | Claudin-18.2:n vasta-aineita sisältävä yhdistelmähoito syövän hoitoon | |
| JP2019536806A5 (enExample) | ||
| JP2019508013A5 (enExample) | ||
| JP2018516911A5 (enExample) | ||
| HRP20230517T1 (hr) | Kombinacija anti-pd-1 antitijela i radijacijske terapije za liječenje raka | |
| HRP20240338T1 (hr) | Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38 | |
| JP2018501218A5 (enExample) | ||
| HRP20201656T1 (hr) | Neutralizacija inhibitornih putova u limfocitima | |
| JP2020527332A5 (enExample) | ||
| JP2020508317A5 (enExample) | ||
| JP2011512332A5 (enExample) | ||
| HRP20160045T1 (hr) | Metoda lijeäśenja raka pomoä†u antagonista dll4 i kemoterapijskog sredstva | |
| JP2016094424A5 (enExample) | ||
| JP2018512402A5 (enExample) | ||
| JP2016511257A5 (enExample) |